Dexrazoxane: A Review of its Use as a Cardioprotective Agent in Patients Receiving Anthracycline-Based Chemotherapy

ISSN： 0012-6667

Source： Drugs, Vol.56, Iss.3, 1998-09, pp. : 385-403

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dexrazoxane: A Review of its Use for Cardioprotection During Anthracycline Chemotherapy

By Cvetkovi

Drugs, Vol. 65, Iss. 7, 2005-01 ,pp. : 1005-1024

Adis International

Access to resources Recommend Favorite

A deletion in chromosome 11q may predict the response to anthracycline-based chemotherapy in patients with early node-negative breast cancer

Inpharma, Vol. 1, Iss. 1578, 2007-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Advanced-Stage Follicular Lymphoma in the Rituximab Era: When Should Patients Receive Anthracycline-Based Chemotherapy?

By Pettengell Ruth

Drugs, Vol. 69, Iss. 13, 2009-09 ,pp. : 1727-1737

Adis International

Access to resources Recommend Favorite

Darbepoetin Alfa: A Review of its Use in the Treatment of Anaemia in Patients with Cancer Receiving Chemotherapy

By Siddiqui M. Asif A. Keating Gillian M.

Drugs, Vol. 66, Iss. 7, 2006-01 ,pp. : 997-1012

Adis International

Access to resources Recommend Favorite

The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity

By Kwok J.C. Richardson D.R.

Redox Report, Vol. 5, Iss. 6, 2000-12 ,pp. : 317-324

Maney Publishing

Access to resources Recommend Favorite